## THE GENERAL ASSEMBLY OF PENNSYLVANIA

## HOUSE RESOLUTION

No. 628

Session of 2019

INTRODUCED BY HANBIDGE, FRANKEL, McCLINTON, MILLARD, WEBSTER, KULIK, SCHLOSSBERG, ISAACSON, RAVENSTAHL, HOHENSTEIN, STEPHENS, RABB, HILL-EVANS, KENYATTA, JOHNSON-HARRELL, KINSEY, SAMUELSON, YOUNGBLOOD, CIRESI, MADDEN, OTTEN, KAUFER, HOWARD, KIM, D. MILLER, DeLUCA, MALAGARI AND RYAN, DECEMBER 9, 2019

AS AMENDED, HOUSE OF REPRESENTATIVES, APRIL 14, 2020

## A RESOLUTION

| 2<br>3<br>4<br>5<br>6<br>7 | legislation that would expand Medicare coverage to include hearing aids—; AND URGING THE CONGRESS OF THE UNITED STATES TO APPROVE THE PROTECTING OUR PHARMACEUTICAL SUPPLY CHAIN FROM CHINA ACT, WHICH WOULD ENSURE THAT THE UNITED STATES IS NOT DEPENDENT ON FOREIGN COUNTRIES FOR PHARMACEUTICAL MANUFACTURING. |  |
|----------------------------|--|--|
| 8                          | WHEREAS, Medicare is a Federal health insurance program for:   |  |
| 9                          | (1) Individuals 65 years of age or older.  |  |
| 10                         | (2) Individuals younger than 65 years of age who have  |  |
| 11                         | certain disabilities.  |  |
| 12                         | (3) Individuals of all ages who have end-stage renal   |  |
| 13                         | disease;   |  |
| 14                         | and  |  |
| 15                         | WHEREAS, Medicare consists of four parts:  |  |
| 16                         | (1) Medicare Part A, which provides hospital insurance.  |  |
| 17                         | (2) Medicare Part B, which provides medical insurance.   |  |
| 18                         | (3) Medicare Part C, which is also known as "Medicare  |  |

- 1 Advantage" and is a type of Medicare health plan offered by a
- 2 private company that includes benefits from Medicare Parts A
- 3 and B and that usually includes benefits from Medicare Part
- 4 D.
- 5 (4) Medicare Part D, which provides prescription drug
- 6 coverage;
- 7 and
- 8 WHEREAS, The Medicare program was signed into law on July 30,
- 9 1965; and
- 10 WHEREAS, More than 2.5 million Americans received hospital
- 11 care covered by Medicare in the first six months of the program;
- 12 and
- WHEREAS, More than 60 million Americans, including more than
- 14 2.7 million residents of this Commonwealth, were enrolled in
- 15 Medicare as of March 2019; and
- 16 WHEREAS, Medicare does not cover hearing exams, hearing aids
- 17 or exams for fitting hearing aids, and only Medicare Part B
- 18 covers diagnostic hearing and balance exams if ordered by a
- 19 doctor to determine the necessity of medical treatment; and
- 20 WHEREAS, There are three types of hearing loss:
- 21 (1) Conductive hearing loss, which involves the outer or
- 22 middle ear.
- 23 (2) Sensorineural hearing loss, which involves the inner
- 24 ear.
- 25 (3) Mixed hearing loss, which involves a combination of
- 26 conductive and sensorineural hearing loss;
- 27 and
- 28 WHEREAS, There are four degrees of hearing loss, including
- 29 mild, moderate, severe and profound hearing loss, all of which
- 30 can impact an individual's work, social life and personal life;

- 1 and
- 2 WHEREAS, While hearing loss can occur at any age, it affects
- 3 an estimated 48 million Americans 12 years of age and older; and
- 4 WHEREAS, Hearing aids can greatly improve the quality of life
- 5 of an individual with hearing loss; and
- 6 WHEREAS, States cannot expand Medicare coverage to include
- 7 hearing aids as it is a Federal program; and
- 8 WHEREAS, Several pieces of legislation have been introduced
- 9 in the Congress of the United States that would expand Medicare
- 10 coverage to include hearing aids; therefore be it AND
- 11 WHEREAS, PROTECTING THE HEALTH AND SAFETY OF AMERICANS IS THE
- 12 PRIMARY JOB OF ELECTED OFFICIALS AT ALL TIMES, BUT ESPECIALLY SO
- 13 DURING THE WORLDWIDE COVID-19 PANDEMIC; AND
- 14 WHEREAS, DOMESTIC PRODUCTION OF LIFE-SUSTAINING DRUGS AND
- 15 MEDICAL EQUIPMENT WILL ENSURE THAT THESE VITAL PRODUCTS MEET THE
- 16 STRINGENT STANDARDS OF THE UNITED STATES; AND
- 17 WHEREAS, THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA)
- 18 HAS WARNED THAT SYSTEMIC PROBLEMS AT DRUG MANUFACTURING
- 19 FACILITIES OVERSEAS, PARTICULARLY IN CHINA AND INDIA, HAVE LED
- 20 TO TAINTED MEDICATION CIRCULATING IN THE UNITED STATES; AND
- 21 WHEREAS, THE FDA ESTIMATES THAT ROUGHLY 85% OF THE FACILITIES
- 22 THAT MANUFACTURE INGREDIENTS IN AMERICAN DRUGS ARE LOCATED
- 23 OVERSEAS; AND
- 24 WHEREAS, IN 2019, MILLIONS OF AMERICANS INGESTED A
- 25 CONTAMINANT FORMERLY USED IN THE PRODUCTION OF ROCKET FUEL
- 26 THROUGH TAINTED BLOOD PRESSURE DRUGS PRODUCED IN CHINA; AND
- 27 WHEREAS, AS MUCH AS 95% OF IBUPROFEN, 70% OF ACETAMINOPHEN
- 28 AND 45% OF PENICILLIN IS MADE IN CHINA; AND
- 29 WHEREAS, AN OVER-RELIANCE ON FOREIGN PRODUCTION OF
- 30 PHARMACEUTICALS AFFECTS THE HEALTH OF AMERICANS AND ALSO THE

- 1 HEALTH OF AMERICA'S ECONOMY; AND
- 2 WHEREAS, THE UNITED STATES SHOULD NOT BE DEPENDENT ON FOREIGN
- 3 COUNTRIES TO SUPPLY VITAL DRUGS DURING A GLOBAL PANDEMIC; AND
- 4 WHEREAS, LAWMAKERS ARE WORRIED ABOUT DRUG SHORTAGES AMID THE
- 5 COVID-19 OUTBREAK AND HAVE TAKEN ACTION TO AID AMERICAN
- 6 MANUFACTURERS IN RECLAIMING PHARMACEUTICAL PRODUCTION; AND
- 7 WHEREAS, THE PROTECTING OUR PHARMACEUTICAL SUPPLY CHAIN FROM
- 8 CHINA ACT WOULD PHASE IN A BAN ON UNITED STATES AGENCIES
- 9 PURCHASING PHARMACEUTICALS WITH ACTIVE INGREDIENTS PRODUCED IN
- 10 CHINA; AND
- 11 WHEREAS, THE BILL WOULD INCREASE TRANSPARENCY BY REQUIRING
- 12 THE FDA TO CREATE A REGISTRY OF ALL DRUGS AND BY REQUIRING DRUG
- 13 COMPANIES TO LIST ACTIVE INGREDIENTS AND THEIR COUNTRIES OF
- 14 ORIGIN ON LABELS; AND
- 15 WHEREAS, THE MEASURE WOULD PROVIDE CRUCIAL INCENTIVES TO RAMP
- 16 UP UNITED STATES MANUFACTURING OF PHARMACEUTICAL DRUGS AND
- 17 MEDICAL DEVICES; THEREFORE BE IT
- 18 RESOLVED, That the House of Representatives of the
- 19 Commonwealth of Pennsylvania urge the Congress of the United
- 20 States to take action on legislation that would expand Medicare
- 21 to include coverage of hearing aids; and be it further
- 22 RESOLVED, That a copy of this resolution be transmitted to <--

<--

- 23 the presiding officers of each house of Congress and to each
- 24 member of Congress from Pennsylvania.
- 25 RESOLVED, THAT THE HOUSE OF REPRESENTATIVES OF THE
- 26 COMMONWEALTH OF PENNSYLVANIA URGE THE CONGRESS OF THE UNITED
- 27 STATES TO APPROVE THE PROTECTING OUR PHARMACEUTICAL SUPPLY CHAIN
- 28 FROM CHINA ACT, WHICH WOULD ENSURE THAT THE UNITED STATES IS NOT
- 29 DEPENDENT ON FOREIGN COUNTRIES FOR PHARMACEUTICAL MANUFACTURING;
- 30 AND BE IT FURTHER

- 1 RESOLVED, THAT A COPY OF THIS RESOLUTION BE TRANSMITTED TO
- 2 THE PRESIDENT OF THE UNITED STATES, THE PRESIDING OFFICERS OF
- 3 EACH HOUSE OF CONGRESS AND TO EACH MEMBER OF CONGRESS FROM
- 4 PENNSYLVANIA.